Ensign Peak Advisors Inc Has $445.80 Million Stock Position in Abbott Laboratories $ABT

Ensign Peak Advisors Inc increased its stake in Abbott Laboratories (NYSE:ABT) by 5.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,277,679 shares of the healthcare product maker’s stock after buying an additional 170,122 shares during the quarter. Abbott Laboratories makes up 0.8% of Ensign Peak Advisors Inc’s holdings, making the stock its 19th biggest position. Ensign Peak Advisors Inc owned about 0.19% of Abbott Laboratories worth $445,797,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Ignite Planners LLC boosted its stake in shares of Abbott Laboratories by 6.3% during the 1st quarter. Ignite Planners LLC now owns 4,742 shares of the healthcare product maker’s stock worth $621,000 after acquiring an additional 280 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $245,000. Old Port Advisors bought a new stake in Abbott Laboratories in the 1st quarter valued at $217,000. Finally, SYM FINANCIAL Corp lifted its holdings in Abbott Laboratories by 109.3% during the 1st quarter. SYM FINANCIAL Corp now owns 7,525 shares of the healthcare product maker’s stock valued at $998,000 after purchasing an additional 3,930 shares during the last quarter. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Down 2.9%

Shares of ABT stock opened at $126.28 on Thursday. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The stock’s fifty day simple moving average is $130.24 and its 200 day simple moving average is $131.30. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $219.58 billion, a P/E ratio of 15.82, a P/E/G ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. The company had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, November 17th. Investors of record on Wednesday, October 15th were issued a $0.59 dividend. The ex-dividend date was Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.9%. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ABT shares. Wells Fargo & Company increased their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Sanford C. Bernstein raised their price objective on shares of Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Royal Bank Of Canada reiterated an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Barclays boosted their price target on Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a research note on Friday, October 17th. Finally, Benchmark started coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.